CoChat

The DOI matches its Crossref record; 49 of the 50 references it cites were found in a registry or an index.

HTA methodology and value frameworks for evaluation and policy making for cell and gene therapies

Coyle, Doug, Durand-Zaleski, Isabelle, Farrington, Jasmine, Garrison, Louis, Graf von der Schulenburg, Johann-Matthias, Greiner, Wolfgang, Longworth, Louise, Meunier, Aurélie, Moutié, Anne-Sophie, Palmer, Stephen, Pemberton-Whiteley, Zack, Ratcliffe, Mark, Shen, Jie, Sproule, Doug, Zhao, Kun, Shah, Koonal · 2020 · The European Journal of Health Economics

Abstract

This last decade has been marked by significant advances in the development of cell and gene (C&G) therapies, such as gene targeting or stem cell-based therapies. C&G therapies offer transformative benefits to patients but present a challenge to current health technology decision-making systems because they are typically reviewed when clinical efficacy data are very limited and when there is uncertainty about the long-term durability of outcomes. These challenges are not unique to C&G therapies, but they face more of these barriers, reflecting the need for adapting existing value assessment frameworks. Still, C&G therapies have the potential to be cost-effective even at very high price points. The impact on healthcare budgets will depend on the success rate of pipeline assets and on the extent to which C&G therapies will expand to wider pathologies beyond rare or ultra-rare diseases. Getting pricing and reimbursement models right is important for incentivising research and development investment while not jeopardising the sustainability of healthcare systems. Payers and manufacturers therefore need to acknowledge each other's constraints-limitations in the evidence generation on the manufacturer side, budget considerations on the payer side-and embrace innovative thinking and approaches to ensure timely delivery of therapies to patients. Several experts in health technology assessment and clinical experts have worked together to produce this publication and identify methodological and policy options to improve the assessment of C&G therapies, and make it happen better, faster and sustainably in the coming years.

Overview

Integrity signals

Registry

Crossref · 10.1007/s10198-020-01212-w

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 50 references

Research works printed but not linked: 2

  1. Food & Drug Administration: Fast track, breakthrough therapy, accelerated approval, priority review, (2018a)
  2. NICE: Guide to the Methods of Technology Appraisal. NICE, London (2013)

Cited by

See all 74

Metadata

Authors
Coyle, D., Durand-Zaleski, I., Farrington, J., Garrison, L., Graf von der Schulenburg, J.-M., Greiner, W., Longworth, L., Meunier, A., Moutié, A.-S., Palmer, S., Pemberton-Whiteley, Z., Ratcliffe, M., Shen, J., Sproule, D., Zhao, K., & Shah, K.
Affiliations
  • University of Ottawa (CA)
  • University of Washington (US)
  • Bielefeld University (DE)
  • University of York (GB)
  • Novartis (Switzerland) (CH)
  • China National Health Development Research Center (CN)
Corresponding author
Moutié, Anne-Sophie
Venue
The European Journal of Health Economics
Published
2020-08-13
Volume
21
Issue
9
Pages
1421-1437
ISSN
  • 1439-3972 (ISSN-L)
  • 1618-7598
  • 1618-7601
OpenAlex
W3049322734
Cited by
71
References
50
Citations by year
2026: 11 · 2025: 4 · 2024: 21 · 2023: 8 · 2022: 11 · 2021: 16
FWCI
7.44
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • The European Journal of Health Economics (publishedVersion)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • PUB – Publications at Bielefeld University (Bielefeld University) (submittedVersion)
Funders
Novartis Pharma
Topics
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
  • Health Sciences › Nursing › Issues, ethics and legal aspects › Biomedical Ethics and Regulation
Keywords
cell and gene therapy, health technology assessment, value assessment framework, cost-effectiveness, pricing and reimbursement, health policy, evidence gaps, rare diseases, stem cell therapy, gene targeting
MeSH terms
Cost-Benefit Analysis, Humans, Policy Making, Technology Assessment, Biomedical, Genetic Therapy, Rare Diseases, Cell- and Tissue-Based Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: HTA methodology and value frameworks for evaluation and policy making for cell and gene therapies. https://app.cochat.ai/papers/10.1007/s10198-020-01212-w
The paper
Coyle, D., Durand-Zaleski, I., Farrington, J., Garrison, L., Graf von der Schulenburg, J.-M., Greiner, W., Longworth, L., Meunier, A., Moutié, A.-S., Palmer, S., Pemberton-Whiteley, Z., Ratcliffe, M., Shen, J., Sproule, D., Zhao, K., & Shah, K. (2020). HTA methodology and value frameworks for evaluation and policy making for cell and gene therapies. The European Journal of Health Economics. https://doi.org/10.1007/s10198-020-01212-w

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.